Natural history of dR modified by anti-VEGF treatment

Analysis of patients with diabetic macular oedema (DME) who participated in the RISE and RIDE phase III trials demonstrates that ranibizumab reduces diabetic retinopathy severity in many patients, and can slow the clinical progression of the disease, according to a presentation at the 13th EURETINA Congress.

“These data underscore the need for early screening and appropriate intervention in DME patients, who without treatment are at high risk of developing proliferative diabetic retinopathy,” said Patricio G Schlottmann MD.